The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A10 | Drugs used in diabetes | |
| 3 | A10B | Blood glucose lowering drugs, excl. insulins | |
| 4 | A10BG | Thiazolidinediones |
| Code | Title | |
|---|---|---|
| A10BG01 | Troglitazone | |
| A10BG02 | Rosiglitazone | |
| A10BG03 | Pioglitazone | |
| A10BG04 |
| Active Ingredient | Description | |
|---|---|---|
| Lobeglitazone |
|
|
| Pioglitazone |
Pioglitazone effects may be mediated by a reduction of insulin resistance. Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance. |
|
| Rosiglitazone |
Rosiglitazone is a selective agonist at the PPARγ (peroxisomal proliferator activated receptor gamma) nuclear receptor and is a member of the thiazolidinedione class of anti-diabetic agents. It reduces glycaemia by reducing insulin resistance at adipose tissue, skeletal muscle and liver. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ACTOS Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| ACTOS Tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| AVANDIA Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| AVANDIA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| GLUSTIN Tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| PIOGLITAZONE ACCORD Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
